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Abstracts / Osteoarthritis and Cartilage 21 (2013) S9–S62 S33Purpose: There is a high unmet medical need for disease modifying
drugs in OA that have an effect on joint structure. Fibroblast growth
factor 18 (FGF18) promotes chondrocyte proliferation and stabilizes an
anabolic chondrocyte phenotype. Data from a proof-of-concept trial in
knee OA demonstrated that sprifermin (rhFGF18) increased total
cartilage volume and thickness. This effect seemed to be more
pronounced in the lateral compartment, raising the question of the
distribution of the effect on cartilage change on different knee subre-
gions. Here we use a location-independent analysis method, to identify
whether sprifermin modiﬁes the magnitude of (subregional) cartilage
loss compared with placebo, independent of the location where it
occurs in individual joints.
Methods: Study participants (n¼168; 40-year-old; 69% female) had
symptomatic and radiographic femorotibial OA (KLG2 or 3), and were
not conﬁned to medial disease. Sprifermin (10, 30, or 100mg) or placebo
were injected once weekly for 3 weeks after randomization, and at 13
weeks. 1.5mm coronal SPGR MRIs were acquired at baseline and 13, 26
and 52 weeks. Medial (MFTC) and lateral femorotibial cartilage (LFTC)
was segmented by 7 readers, with blinding to acquisition order and
treatment (Chondrometrics GmbH). Cartilage thickness (changes) were
computed in each of 16 femorotibial subregions (5 medial and 5 lateral
tibial, 3 medial and 3 lateral femoral).The location-independent
magnitude of subregional thickness changes (in mm) was calculated
using ordered values (OV), individually assigning the magnitude of
cartilage loss in the subregion with the greatest loss to OV1, the one
with the second greatest loss to OV2, and so forth, and the one with the
smallest loss/greatest increase to OV16). In the current analysis, results
of the 100mg cohort (n¼63) vs. matching placebo (n¼21) were
compared using t-tests.
Results: Total femorotibial cartilage thickness loss at 52 weeks was less
in sprifermin treated than in placebo treated knees, with effects being
signiﬁcant in LFTC (p¼0.03) but not MFTC (p¼0.16) (Table 1). Signiﬁcant
treatment effects (p<0.05) were detected in 2/16 subregions (minimal
p-value ¼0.006 in the external lateral femur), and in 10/16 OVs
(minimal p¼0.004 in OV12). The 10 OVs included some in which
cartilage loss was observed (OV4-8) and some in which cartilage
thickening was observed in the placebo group (OV11-15).
Conclusions: This location-independent analysis shows that sprifermin
can modify the magnitude of cartilage loss in subregions with low OVs,
where (individual) mechanical challenges may be greater and drug
effects may be more important clinically. The OV approach also has the
advantage that no single region must be deﬁned a priori as structural
endpoint, which is challenging given spatial inter-subject heterogeneity
of (subregional) cartilage loss in OA, particularly in cohorts without
predeﬁned (medial or lateral) involvement. The results further show
that OVs are more effective and informative in revealing structural
treatment effects than region-based analysis, and that sprifermin not
only increases cartilage thickness (in regions where no loss is observed),
but actually reduces cartilage loss (in regions where cartilage loss is
observed with placebo).Table 1
Cartilage thickness change (mm) in sprifermin treated vs. placebo knees
Placebo
Mean  SD change
100mg dose
Mean  SD change
Difference
Effect-Size
p value
MFTC -0.07  0.18 0.00  0.16 0.43 0.1603
LFTC -0.04  0.19 0.04  0.12 0.58 0.0323
SRmax -0.03  0.11 0.04  0.09 0.78 0.0055
OV1 -0.22  0.16 -0.18  0.15 0.25 0.3529
OV2 -0.15  0.12 -0.12  0.12 0.25 0.3500
OV3 -0.12  0.09 -0.09  0.09 0.39 0.1571
OV4 -0.10  0.08 -0.05  0.07 0.64 0.0198
OV5 -0.08  0.07 -0.04  0.06 0.73 0.0094
OV6 -0.07  0.06 -0.02  0.06 0.79 0.0057
OV7 -0.05  0.06 -0.01  0.06 0.69 0.0132
OV8 -0.03  0.06 0.01  0.05 0.62 0.0244
OV9 -0.01  0.06 0.02  0.05 0.50 0.0708
OV10 0.01  0.06 0.03  0.05 0.49 0.0739
OV11 0.02  0.06 0.05  0.05 0.64 0.0210
OV12 0.03  0.07 0.06  0.04 0.80 0.0044
OV13 0.04  0.06 0.08  0.05 0.78 0.0065
OV14 0.07  0.07 0.10  0.05 0.64 0.0232
OV15 0.09  0.07 0.13  0.06 0.60 0.0305
OV16 0.15  0.10 0.18  0.07 0.35 0.212450
MALALIGNMENT; A POSSIBLE TARGET FOR PREVENTION OF
INCIDENT KNEE OA IN MIDDLE-AGED OVERWEIGHT AND OBESE
WOMEN
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Oei y, S.M. Bierma-Zeinstra y. y Erasmus MC, Rotterdam, Netherlands;
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Purpose: The present study evaluates the effects of malalignment and
its interaction with BMI on the onset of clinical and radiographic knee
osteoarthritis (OA) over a 2.5 year follow-up period in a high risk group
of middle-aged overweight and obese women.
Methods: Data of the PROOF study (ISRCTN 42823086) were used. In
total, 407 women between 50 and 60 years, with a BMI 27 kg/m2, and
without clinical and radiological knee OA at baseline were included in
this study. Both knees of all 351 women (86%) with baseline knee
alignment data and the primary outcome available were selected. At
baseline, body weight and height were measured and standardized
semi-ﬂexed PA radiographs of both knees were taken according to the
MTP protocol. All subjects ﬁlled in a questionnaire with questions on
knee complaints and number of days with knee pain. All measurements
were repeated after 2.5 years of follow-up. Minimal joint space width
(medial and lateral), K&L grade and anatomical knee alignment angle
were digitally assessed on all radiographs. Varus alignment was deﬁned
as an anatomical angle 184. The predeﬁned primary outcome measure
was the incidence of knee OA, deﬁned as onset of K&L 2 or the onset of
clinical knee OA (according to the ACR criteria), or joint space narrowing
(JSN) 1.0 mm in themedial or lateral compartment. Using Generalized
Estimated Equations, which takes into account the correlation between
knees within subjects, effects of varus and valgus alignment on the
primary outcome and on the items separately were evaluated, with
neutrally aligned knees serving as reference. The interaction between
malalignment and baseline BMI was also studied, by adding BMI and
the interaction term with malalignment to the analysis. If a signiﬁcant
interactionwas found, overweight (BMI< 30 kg/m2) and obese subjects
(BMI  30 kg/m2) were analysed separately. All analyses were adjusted
for K&L grade at baseline and the randomized groups of the interven-
tions of the PROOF study.
Results: Varus alignment was found in 40% and valgus alignment in 13%
of all knees. Baseline characteristics are presented in Table 1. Overall,
only varus alignment had a signiﬁcant effect on the incidence of K&L 2
(9% vs. 3% in neutral knees. OR 2.8, 95% CI 1.3 - 5.9). For the primary
outcome and for medial JSN a signiﬁcant interaction between mala-
lignment and baseline BMI was found (p < 0.01). In obese subjects,
varus alignment had a signiﬁcant effect on the primary outcome (22%
vs. 13% in neutral knees. OR 1.8, 95% CI 1.1 - 3.1) and on medial JSN (9%
vs. 4% in neutral knees. OR 2.6, 95% CI 1.1 - 6.3). These associations were
not found in non-obese subjects.
Conclusions: In women at high risk for developing knee OA, varus
aligned knees had a signiﬁcant increased risk for the development of
radiographickneeOA.Withinobesewomen, varus alignedknees alsohad
a signiﬁcantly increased risk for incidence of knee OA according to the
primary outcome and for joint space narrowing in the medial compart-
ment. Since varus alignment is a potentially modiﬁable factor, results
from the present study suggest that varus alignmentmight be a target for
the prevention of knee OA inmiddle-aged overweight and obesewomen.51
DOES CARTILAGE THICKNESS CHANGE DIFFER BETWEEN ACL
DEFICIENT KNEES WITH ANDWITHOUT RECONSTRUCTION SURGERY
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Clinical Sci. Lund, Lund Univ., Lund, Sweden
Purpose: An ACL tear is a common knee injury, involving a serious
trauma and a subsequent period of chronic alterations in joint biome-
chanics. The risk of developing incident knee OA after an ACL tear is
known to be highly elevated although the driving mechanisms are not
known. In this study, we tested the hypothesis that treatment of the
initial injury inﬂuenced change in femorotibial cartilage thickness over
the ﬁrst ﬁve years after injury. We thus explored femorotibial cartilage
thickness changes during the ﬁrst 2 years (BL/Y2) and during
a subsequent three-year period (Y2/Y5) after an acute ACL tear.
